|
1
|
Peto R, Davies C, Godwin J, Gray R, Pan
HC, Clarke M, Cutter D, Darby S, McGale P, Taylor C, et al: Early
Breast Cancer Trialists' Collaborative Group (EBCTCG): Comparisons
between different polychemotherapy regimens for early breast
cancer: Meta-analyses of long-term outcome among 100,000 women in
123 randomised trials. Lancet. 379:432–444. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gianni L, Norton L, Wolmark N, Suter TM,
Bonadonna G and Hortobagyi GN: Role of anthracyclines in the
treatment of early breast cancer. J Clin Oncol. 27:4798–4808. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ellis P, Smith I, Ashley S, Walsh G, Ebbs
S, Baum M, Sacks N and McKinna J: Clinical prognostic and
predictive factors for primary chemotherapy in operable breast
cancer. J Clin Oncol. 16:107–114. 1998.PubMed/NCBI
|
|
4
|
Bonadonna G, Valagussa P, Brambilla C and
Ferrari L: Preoperative chemotherapy in operable breast cancer.
Lancet. 341:14851993. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fisher B, Bryant J, Wolmark N, Mamounas E,
Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux
A, et al: Effect of preoperative chemotherapy on the outcome of
women with operable breast cancer. J Clin Oncol. 16:2672–2685.
1998.PubMed/NCBI
|
|
6
|
Smith IE, Walsh G, Jones A, Prendiville J,
Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S,
et al: High complete remission rates with primary neoadjuvant
infusional chemotherapy for large early breast cancer. J Clin
Oncol. 13:424–429. 1995.PubMed/NCBI
|
|
7
|
Kaufmann M, von Minckwitz G, Smith R,
Valero V, Gianni L, Eiermann W, Howell A, Costa SD, Beuzeboc P,
Untch M, et al: International expert panel on the use of primary
(preoperative) systemic treatment of operable breast cancer: Review
and recommendations. J Clin Oncol. 21:2600–2608. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chang J, Powles TJ, Allred DC, Ashley SE,
Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK and Dowsett
M: Biologic markers as predictors of clinical outcome from systemic
therapy for primary operable breast cancer. J Clin Oncol.
17:3058–3063. 1999.PubMed/NCBI
|
|
9
|
Minotti G, Menna P, Salvatorelli E, Cairo
G and Gianni L: Anthracyclines: Molecular advances and
pharmacologic developments in antitumor activity and
cardiotoxicity. Pharmacol Rev. 56:185–229. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kellner U, Sehested M, Jensen PB, Gieseler
F and Rudolph P: Culprit and victim - DNA topoisomerase II. Lancet
Oncol. 3:235–243. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fry AM, Chresta CM, Davies SM, Walker MC,
Harris AL, Hartley JA, Masters JR and Hickson ID: Relationship
between topoisomerase II level and chemosensitivity in human tumor
cell lines. Cancer Res. 51:6592–6595. 1991.PubMed/NCBI
|
|
12
|
Di Leo A, Gancberg D, Larsimont D, Tanner
M, Jarvinen T, Rouas G, Dolci S, Leroy JY, Paesmans M, Isola J, et
al: HER-2 amplification and topoisomerase II alpha gene aberrations
as predictive markers in node-positive breast cancer patients
randomly treated either with an anthracycline-based therapy or with
cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer
Res. 8:1107–1116. 2002.PubMed/NCBI
|
|
13
|
Du Y, Zhou Q, Yin W, Zhou L, Di G, Shen Z,
Shao Z and Lu J: The role of topoisomerase IIα in predicting
sensitivity to anthracyclines in breast cancer patients: A
meta-analysis of published literatures. Breast Cancer Res Treat.
129:839–848. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Leo A, Desmedt C, Bartlett JM, Piette
F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl
H, et al: HER2/TOP2A Meta-analysis Study Group: HER2 and TOP2A as
predictive markers for anthracycline-containing chemotherapy
regimens as adjuvant treatment of breast cancer: A meta-analysis of
individual patient data. Lancet Oncol. 12:1134–1142. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Perou CM, Sørlie T, Eisen MB, van de Rijn
M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA,
et al: Molecular portraits of human breast tumours. Nature.
406:747–752. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sørlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Carey LA, Dees EC, Sawyer L, Gatti L,
Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou
CM: The triple negative paradox: Primary tumor chemosensitivity of
breast cancer subtypes. Clin Cancer Res. 13:2329–2334. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nogi H, Kobayashi T, Suzuki M, Tabei I,
Kawase K, Toriumi Y, Fukushima H and Uchida K: EGFR as paradoxical
predictor of chemosensitivity and outcome among triple-negative
breast cancer. Oncol Rep. 21:413–417. 2009.PubMed/NCBI
|
|
20
|
Sørlie T, Perou CM, Fan C, Geisler S, Aas
T, Nobel A, Anker G, Akslen LA, Botstein D, Børresen-Dale AL, et
al: Gene expression profiles do not consistently predict the
clinical treatment response in locally advanced breast cancer. Mol
Cancer Ther. 5:2914–2918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martin M, Romero A, Cheang MC, López
García-Asenjo JA, García-Saenz JA, Oliva B, Román JM, He X, Casado
A, de la Torre J, et al: Genomic predictors of response to
doxorubicin versus docetaxel in primary breast cancer. Breast
Cancer Res Treat. 128:127–136. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, et al:
Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical Oncology:
College of American Pathologists clinical practice guideline
update. J Clin Oncol. 31:3997–4013. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Berger JM, Gamblin SJ, Harrison SC and
Wang JC: Structure and mechanism of DNA topoisomerase II. Nature.
379:225–232. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smith K, Houlbrook S, Greenall M,
Carmichael J and Harris AL: Topoisomerase II alpha co-amplification
with erbB2 in human primary breast cancer and breast cancer cell
lines: Relationship to m-AMSA and mitoxantrone sensitivity.
Oncogene. 8:933–938. 1993.PubMed/NCBI
|
|
25
|
Järvinen TA, Tanner M, Rantanen V, Bärlund
M, Borg A, Grénman S and Isola J: Amplification and deletion of
topoisomerase IIalpha associate with ErbB-2 amplification and
affect sensitivity to topoisomerase II inhibitor doxorubicin in
breast cancer. Am J Pathol. 156:839–847. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Arriola E, Moreno A, Varela M, Serra JM,
Falo C, Benito E and Escobedo AP: Predictive value of HER-2 and
Topoisomerase II alpha in response to primary doxorubicin in breast
cancer. Eur J Cancer. 42:2954–2960. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Arriola E, Rodriguez-Pinilla SM, Lambros
MB, Jones RL, James M, Savage K, Smith IE, Dowsett M and Reis-Filho
JS: Topoisomerase II alpha amplification may predict benefit from
adjuvant anthracyclines in HER2 positive early breast cancer.
Breast Cancer Res Treat. 106:181–189. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Coon JS, Marcus E, Gupta-Burt S, Seelig S,
Jacobson K, Chen S, Renta V, Fronda G and Preisler HD:
Amplification and overexpression of topoisomerase IIalpha predict
response to anthracycline-based therapy in locally advanced breast
cancer. Clin Cancer Res. 8:1061–1067. 2002.PubMed/NCBI
|
|
29
|
Durbecq V, Desmed C, Paesmans M, Cardoso
F, Di Leo A, Mano M, Rouas G, Leroy JY, Sotiriou C, Piccart M, et
al: Correlation between topoisomerase-IIalpha gene amplification
and protein expression in HER-2 amplified breast cancer. Int J
Oncol. 25:1473–1479. 2004.PubMed/NCBI
|
|
30
|
Mueller RE, Parkes RK, Andrulis I and
O'Malley FP: Amplification of the TOP2A gene does not predict high
levels of topoisomerase II alpha protein in human breast tumor
samples. Genes Chromosomes Cancer. 39:288–297. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Campiglio M, Somenzi G, Olgiati C, Beretta
G, Balsari A, Zaffaroni N, Valagussa P and Ménard S: Role of
proliferation in HER2 status predicted response to doxorubicin. Int
J Cancer. 105:568–573. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sotiriou C, Neo SY, McShane LM, Korn EL,
Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL and Liu ET: Breast
cancer classification and prognosis based on gene expression
profiles from a population-based study. Proc Natl Acad Sci USA.
100:10393–10398. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheang MC, Chia SK, Voduc D, Gao D, Leung
S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, et al: Ki67
index, HER2 status and prognosis of patients with luminal B breast
cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar : PubMed/NCBI
|
